Session

Improved monitoring for disease activity in IBD

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

Improved monitoring for disease activity in IBD  et al.

HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN
HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN

Improved monitoring for disease activity in IBD  et al.

HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD
HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD

Improved monitoring for disease activity in IBD  et al.

FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Improved monitoring for disease activity in IBD  et al.

DIAGNOSTIC PERFORMANCE OF SONOGRAPHIC ACTIVITY SCORES FOR ADULT TERMINAL ILEAL CROHN’S DISEASE COMPARED TO MAGNETIC RESONANCE ENTEROGRAPHY AND HISTOLOGICAL REFERENCE STANDARDS: EXPERIENCE FROM THE METRIC TRIAL
DIAGNOSTIC PERFORMANCE OF SONOGRAPHIC ACTIVITY SCORES FOR ADULT TERMINAL ILEAL CROHN’S DISEASE COMPARED TO MAGNETIC RESONANCE ENTEROGRAPHY AND HISTOLOGICAL REFERENCE STANDARDS: EXPERIENCE FROM THE METRIC TRIAL

Improved monitoring for disease activity in IBD  et al.

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
FLUORESCENTLY LABELLED VEDOLIZUMAB VISUALIZES LOCAL DRUG DISTRIBUTION DURING COLONOSCOPY AND IDENTIFIES MUCOSAL TARGET CELLS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN
HIGHER PERFORMANCE OF FAECAL MICROBIAL MARKERS TO MONITOR ENDOSCOPIC ACTIVITY IN CROHN’S DISEASE, AS COMPARED TO FAECAL CALPROTECTIN

DIAGNOSTIC PERFORMANCE OF SONOGRAPHIC ACTIVITY SCORES FOR ADULT TERMINAL ILEAL CROHN’S DISEASE COMPARED TO MAGNETIC RESONANCE ENTEROGRAPHY AND HISTOLOGICAL REFERENCE STANDARDS: EXPERIENCE FROM THE METRIC TRIAL
DIAGNOSTIC PERFORMANCE OF SONOGRAPHIC ACTIVITY SCORES FOR ADULT TERMINAL ILEAL CROHN’S DISEASE COMPARED TO MAGNETIC RESONANCE ENTEROGRAPHY AND HISTOLOGICAL REFERENCE STANDARDS: EXPERIENCE FROM THE METRIC TRIAL

HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD
HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD

Item 1 - 10 / 10
1